03 April 2012 - Biotica to present at the EASL International Liver Congress 2012 in Barcelona
BC556, a potent, pan-genotypic, high barrier to resistance, second generation cyclophilin inhibitor for treatment of chronic HCV infection
03 January 2012 - Biotica moves to new business premises on Granta Park, Cambridge
Company moves to new custom built state-of-the-art research facility.
31 October 2011 - Biotica nominates drug candidate, BC556, a cyclophilin inhibitor to treat Hepatitis C
Cyclophilin inhibition provides a high barrier to viral resistance in combination therapy.
24 October 2011 - Biotica announces the Sangamides
Biotica announces the Sangamides: a new class of compounds with potential to provide a key component of combination therapy in Hepatitis C.
14 September 2011 - Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan
The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging. Building on observations that rapamycin extends healthy lifespan in various species (Kaeberlein & Kennedy; Nature 2009), the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.
BC556, a potent, pan-genotypic, high barrier to resistance, second generation cyclophilin inhibitor for treatment of chronic HCV infection
03 January 2012 - Biotica moves to new business premises on Granta Park, Cambridge
Company moves to new custom built state-of-the-art research facility.
31 October 2011 - Biotica nominates drug candidate, BC556, a cyclophilin inhibitor to treat Hepatitis C
Cyclophilin inhibition provides a high barrier to viral resistance in combination therapy.
24 October 2011 - Biotica announces the Sangamides
Biotica announces the Sangamides: a new class of compounds with potential to provide a key component of combination therapy in Hepatitis C.
14 September 2011 - Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan
The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging. Building on observations that rapamycin extends healthy lifespan in various species (Kaeberlein & Kennedy; Nature 2009), the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.